Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine... see more

NDAQ:PMN - Post Discussion

ProMIS Neurosciences Inc > Roche gets go ahead for their serology test
View:
Post by retiredcop on Dec 03, 2020 10:01am

Roche gets go ahead for their serology test

I am trying to get this confirmed, but I believe that PMN's serology test uses a different science. This approval gives a person a good idea what the inteneded uses are for these tests 

 1- to verify the effectiveness of the new vaccine 
 2- to assist  to identify potential donors for expermental blood plasma transfer of plasma from recovered covid victims to people being treated for covid infection. Not alot know about this process, but in one European country, they have collected 2200 litres of blood from recovered covid patients, as they investigate this possible treatement . 

__________________________________________________________________________ 
Emma Court
December 1, 2020, 11:20 AM MST
 
Roche Holding AG test that detects the presence and level of coronavirus antibodies inside people was cleared by the U.S. Food and Drug Administration for emergency use.
The test, known as the Elecsys Anti-SARS-CoV-2 S, identifies antibodies tied to the virus’s distinctive spike protein, a target for several of the leading vaccines in development. The test could be used to evaluate how well the shots work, including over time, Roche said in a statement announcing the approval.
Like other antibody tests, it could also be used to identify potential plasma donors. The use of so-called convalescent plasma to treat people hospitalized with Covid-19 was granted emergency authorization by the FDA earlier this year.
 
Similar tests from Siemens Healthineers AG, cleared by the FDA in late July, were the first such tests to get a green light in the U.S.
 
Roche will begin shipping the new antibody test to U.S. laboratories in the next week, where it will be processed using a Roche automated platform that produces results in about 18 minutes. Laboratory Corp of America Holdings will be the first to offer the tests.
Comment by Gbathat on Dec 03, 2020 1:03pm
looks like it uses a roche electrochemiluminescence detector coupled with sandwich assay.  98.8% sensitivity, > 99.9% clinical specificity; limited data on serum neutralization
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities